Apr 24 |
Kiniksa Pharmaceuticals First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
|
Apr 24 |
Kiniksa Pharmaceuticals: Arcalyst Performs While Abiprubart Plans Take Shape
|
Apr 24 |
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q1 2024 Earnings Call Transcript
|
Apr 23 |
Kiniksa Pharmaceuticals, Ltd. (KNSA) Q1 2024 Earnings Call Transcript
|
Apr 23 |
Kiniksa Pharmaceuticals, Ltd. 2024 Q1 - Results - Earnings Call Presentation
|
Apr 23 |
Kiniksa Pharmaceuticals Ltd (KNSA) Q1 2024 Earnings Overview: Surpasses Revenue Forecasts
|
Apr 23 |
Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q1 Loss, Tops Revenue Estimates
|
Apr 23 |
Kiniksa Pharmaceuticals reports mixed Q1 results; raises FY24 outlook
|
Apr 23 |
Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio Execution
|
Apr 22 |
Kiniksa Pharmaceuticals Q1 2024 Earnings Preview
|